Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
10 pending office actions • 4 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Paul Scherrer Institut currently faces 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 10 actions are distributed among 10 distinct examiners, showing a high degree of examiner diversity. Despite this volume, the work is concentrated within 4 distinct art units. MCAVOY, ELLEN M is the busiest examiner, yet handles only 1 pending action.
This distribution suggests that the institute's prosecution is fragmented across many individuals, even though the subject matter remains within the 4 distinct art units. For a practitioner, this fragmentation means that there is no examiner whose historical patterns will dominate the portfolio's outcome. Instead, the strategy must account for the different perspectives across the art units. The fact that the busiest examiner only manages 1 action highlights the distribution of the workload.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 4 (40%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCAVOY, ELLEN M | 1 | 72.8% | +8.7% |
| BROWN, MINDY G | 1 | 55.9% | +44.4% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| TAYLOR, JORDAN W | 1 | 63.2% | +36.9% |
| GZYBOWSKI, MICHAEL STANLEY | 1 | 68.3% | +52.0% |
| ROGERS, JAMES WILLIAM | 1 | 46.2% | +22.3% |
| BLACKWELL-RUDASIL, RYAN KENZIE | 1 | 61.9% | +30.0% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719462 | METHOD AND PLANT FOR OBTAINING A MAIN PRODUCT STREAM FOR THE PRODUCTION OF TRANSPORT FUEL | MCAVOY, ELLEN M | — |
| 18696532 | METHOD FOR PREDICTING THE RESPONSE OF A PATIENT DIAGNOSED WITH CANCER TO TREATMENT AND/OR IMAGING WITH A COMPOUND TARGETING CCK2-R, AND COMPOUND FOR USE IN METHODS OF SELECTIVELY TREATING AND/OR IMAGING CANCER | BROWN, MINDY G | — |
| 18604709 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | XIAO, YAN | — |
| 18566216 | Isolated Metal Species in Metal-Zeolite Catalytic Material for Low Temperature SCR of NOx with NH3 | TAYLOR, JORDAN W | — |
| 18552124 | [161Tb]-BASED RADIOPEPTIDES | ROGERS, JAMES WILLIAM | — |
| 18040021 | ALPHA RADIOLABELED GASTRIN ANALOGUE AND USE THEREOF IN METHODS OF TREATING CCKB RECEPTOR POSITIVE DISEASES | WESTERBERG, NISSA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040024 | GALLIUM-LABELED GASTRIN ANALOGUE AND USE IN A METHOD OF IMAGING CCKB-RECEPTOR-POSITIVE TUMORS OR CANCERS | YOUNG, MICAH PAUL | 8d |
| 18040011 | COMPOSITION COMPRISING A RAPALOG AND A RADIOLABELLED GASTRIN ANALOGUE, IN PARTICULAR FOR USE IN THE TREATMENT AND/OR DIAGNOSIS OF CCKB RECEPTOR POSITIVE CANCER OR TUMORS | SCHLIENTZ, LEAH H | 26d |
| 18696532 | METHOD FOR PREDICTING THE RESPONSE OF A PATIENT DIAGNOSED WITH CANCER TO TREATMENT AND/OR IMAGING WITH A COMPOUND TARGETING CCK2-R, AND COMPOUND FOR USE IN METHODS OF SELECTIVELY TREATING AND/OR IMAGING CANCER | BROWN, MINDY G | — |
| 18604709 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | XIAO, YAN | — |
| 18566216 | Isolated Metal Species in Metal-Zeolite Catalytic Material for Low Temperature SCR of NOx with NH3 | TAYLOR, JORDAN W | — |
| 18559099 | A NANOFLUIDIC DEVICE FOR RAPID AND MULTIPLEXED SEROLOGICAL ANTIBODY DETECTION | GZYBOWSKI, MICHAEL STANLEY | — |
| 18552124 | [161Tb]-BASED RADIOPEPTIDES | ROGERS, JAMES WILLIAM | — |
| 18041571 | A METHOD FOR PREPARING NANOMETER-SIZED SURFACE FLUORINATED BATTERY MATERIALS | BLACKWELL-RUDASIL, RYAN KENZIE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 4 |
| 1771 | 1 |
| 1798 | 1 |
| 1722 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18719462 | METHOD AND PLANT FOR OBTAINING A MAIN PRODUCT STREAM FOR THE PRODUCTION OF TRANSPORT FUEL | MCAVOY, ELLEN M | 1771 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18696532 | METHOD FOR PREDICTING THE RESPONSE OF A PATIENT DIAGNOSED WITH CANCER TO TREATMENT AND/OR IMAGING WITH A COMPOUND TARGETING CCK2-R, AND COMPOUND FOR USE IN METHODS OF SELECTIVELY TREATING AND/OR IMAGING CANCER | BROWN, MINDY G | — | §101§102§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18604709 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | XIAO, YAN | — | §102§112Other | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18566216 | Isolated Metal Species in Metal-Zeolite Catalytic Material for Low Temperature SCR of NOx with NH3 | TAYLOR, JORDAN W | — | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18559099 | A NANOFLUIDIC DEVICE FOR RAPID AND MULTIPLEXED SEROLOGICAL ANTIBODY DETECTION | GZYBOWSKI, MICHAEL STANLEY | 1798 | §103 | Final Rejection | — | Pending | Nov 06, 2023 |
| 18552124 | [161Tb]-BASED RADIOPEPTIDES | ROGERS, JAMES WILLIAM | 1618 | §102§103 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18041571 | A METHOD FOR PREPARING NANOMETER-SIZED SURFACE FLUORINATED BATTERY MATERIALS | BLACKWELL-RUDASIL, RYAN KENZIE | 1722 | §103 | Non-Final OA | — | Pending | Feb 14, 2023 |
| 18040024 | GALLIUM-LABELED GASTRIN ANALOGUE AND USE IN A METHOD OF IMAGING CCKB-RECEPTOR-POSITIVE TUMORS OR CANCERS | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | 8d | Pending | Jan 31, 2023 |
| 18040011 | COMPOSITION COMPRISING A RAPALOG AND A RADIOLABELLED GASTRIN ANALOGUE, IN PARTICULAR FOR USE IN THE TREATMENT AND/OR DIAGNOSIS OF CCKB RECEPTOR POSITIVE CANCER OR TUMORS | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | 26d | Pending | Jan 31, 2023 |
| 18040021 | ALPHA RADIOLABELED GASTRIN ANALOGUE AND USE THEREOF IN METHODS OF TREATING CCKB RECEPTOR POSITIVE DISEASES | WESTERBERG, NISSA M | 1618 | §103DP | Non-Final OA | — | Pending | Jan 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial